With shares of Amazon (NASDAQ:AMZN) trading around $386, is AMZN an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s MovementAmazon serves its customers through its retail websites and focus on selection, price, and convenience. The company also manufactures and sells Kindle devices. Amazon offers programs that enable sellers to sell their products on the company�� websites, including the sellers��own branded websites, and fulfill orders through them. Amazon also provides platforms that allow authors, musicians, filmmakers, app developers, and others to publish and sell content. Online commerce has been on the rise because of the convenience, efficiency, and relatively low prices offered.
While the e-retailer already offers its own brand of batteries, keyboards, and bedding, Amazon is looking to expand its private-label products to grocery store shelves. AllThingsD reports that recent job listings indicate that Amazon is making the push into supermarkets. The possibilities range from groceries to health and personal care to baby products; the AmazonFresh grocery delivery operation is also a part of the division, according to the news outlet.
Top 10 High Tech Companies To Watch In Right Now: Crosstex Energy L.P.(XTEX)
Crosstex Energy, L.P. operates as an independent midstream energy company. The company, through its subsidiary, Crosstex Energy Services, L.P., engages in gathering, transmission, processing, and marketing natural gas and natural gas liquids (NGLs) in the north Texas Barnett shale area and Louisiana. Its activities include connecting the wells of natural gas producers to its gathering systems; processing natural gas for the removal of NGLs; fractionating NGLs into purity products, such as ethane, propane, isobutene, normal butane, natural gasoline, and stabilized condensate; marketing those NGL products; transporting natural gas; and providing it to various markets. The company also purchases natural gas from natural gas producers and other supply sources, and sells that natural gas to utilities, industrial consumers, and other marketers and pipelines. In addition, it purchases natural gas from producers not connected to its gathering systems for resale. The company operat es approximately 3,300 miles of natural gas gathering and transmission, and NGL pipelines. Crosstex Energy GP, LLC serves as the general partner of the company. Crosstex Energy, L.P. was founded in 1992 and is headquartered in Dallas, Texas.
Advisors' Opinion:- [By Paul Ausick]
Crosstex Energy�� (XTXI) shares are up 59.4% at $32.84 after posting a new 52-week high of $34.21. Crosstex Energy LP�� (XTEX) shares are up 38% at $28.08 after putting up a new high of $29.50 earlier.
- [By Matt DiLallo]
While the data is by no means conclusive, it is a risk that bears watching. A variety of companies are drilling these disposal wells, with master limited partnerships like Crosstex Energy (NASDAQ: XTEX ) being one of the many to watch. The company owns an interest in seven disposal wells in Ohio and West Virginia with another well coming on line soon. These wells are designed to simply dispose of the wastewater. Even if the wells prove not to be the cause, the business of owning disposal wells could be tougher to grow because of the�perceived�risk.
- [By Robert Rapier]
Some of the criteria for inclusion into this index are that units must have a market capitalization of at least $500 million and trade on the New York Stock Exchange or the Nasdaq. Component partnerships will have also maintained or grown distributions quarter-over-quarter for at least one of the trailing two quarters, and they must have a policy intended to consistently maintain or increase distributions over time (i.e., no variable-distribution MLPs).
Because this is an equal-weighted, periodically rebalanced index, top holdings show the MLPs that have outperformed the overall index, while the biggest losers will be found at the bottom of the portfolio. Presently, Crosstex Energy (Nasdaq: XTEX) comprises 6.4 percent of the overall index, reflecting its nearly 30 percent gain in October. Regency Energy Partners (NYSE: RGP) has been the laggard of the group (albeit just barely), falling to 4.84 percent of the overall index makeup.
The total market cap of the ANGI is $190 billion, and the one-, three- and five-year total returns are 29 percent, 52 percent and 249 percent. The index yield is 6 percent.
- [By Seth Jayson]
Crosstex Energy (Nasdaq: XTEX ) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Crosstex Energy missed estimates on revenues and exceeded expectations on earnings per share.
Best Low Price Companies To Buy Right Now: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.
Advisors' Opinion:- [By MONEYMORNING]
We saw this last year with such Private Briefing recommendations as The Boeing Co. (NYSE: BA) and Pharmacyclics Inc. (Nasdaq: PCYC), which rose more than 100% and 400%, respectively, following our recommendation.
- [By Maxx Chatsko]
The astounding rise of Pharmacyclics (NASDAQ: PCYC ) through the markets has been largely based on its BTK inhibitor ibrutinib, which is being evaluated in four types of blood cancers and in a preclinical study for autoimmune indications. The rise is no fluke, either. Ibrutinib has shown very promising results in two phase 2 trials as a monotherapy and will soon be moved to phase 3 trials for both. With billions of dollars between the lymphoma and autoimmune markets up for grabs, it is easy to see why shares have risen 2,000% since the company acquired its lead drug candidate in 2006. Can Celgene tap into this multibillion opportunity with CC-292? Ask me again in about five years.�
- [By Sean Williams]
Biotechnology juggernaut Pharmacyclics (NASDAQ: PCYC ) -- a company that has returned close to 19,000% since its recession lows -- ignited investor optimism when it and licensing partner Johnson & Johnson (NYSE: JNJ ) filed a new drug application for ibrutinib. This is truly exciting news, because it marks the first breakthrough therapy drug that's filed for an NDA, and will act the test subject to the rest of the breakthrough therapy designated drugs. Ibrutinib delivered exceptional results in chronic lymphocytic leukemia and mantle cell lymphoma in terms of overall response rate, which should probably net it an approval from the Food and Drug Administration.
Best Low Price Companies To Buy Right Now: Sterling Consolidated Corp (STCC)
Sterling Consolidated Corp., incorporated on January 31, 2011, is a holding company. The Company�� operations are conducted through its four subsidiaries: Sterling Seal & Supply, Inc. (Sterling Seal), ADDR Properties, LLC (ADDR), Q5 Ventures, LLC (Q5), and Integrity Cargo Freight Corporation (Integrity). The Company through its subsidiary, Sterling Seal engages primarily in the distribution and sale of O-rings, rubber seals, oil seals, custom molded rubber parts, custom Teflon parts, Teflon rods, O-ring cord, bonded seals, O-ring kits, and stuffing box sealant. The Company also owns real property through its subsidiaries ADDR and Q5. In addition, the Company�� subsidiary Integrity Cargo Freight Corporation (Integrity) is a freight forwarding business. In September 2013, the Company announced the acquisition of Superior Seals and Service in High Point, NC.
Sterling Seal sells directly to smaller distributors and original equipment manufacturers in need of seals. It offers a catalogue of standard sizes, and will take orders for special sizes not available in the standard catalogue. O-rings and the other products that Sterling Seal sells are used in a variety of industries, including automotive, pump, transmissions, oil and energy, machinery, and packaging. Integrity are primarily responsible for transporting products the Company order from its suppliers back to its warehouse in Neptune, NJ. After Sterling Seal confirms from its supplier that a product is ready to be picked up, Integrity Cargo is responsible for picking up the products and getting them to the dock and delivered to the Sterling Seal warehouse. ADDR owns a 28,000 square foot facility in Neptune, NJ. Q5 Ventures, LLC owns a 5,000 square foot facility in Apopka, Florida, which is used by Sterling Seal for its Florida operations.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Muscle Warfare International (OTCMKTS: MWAR), Portlogic Systems Inc (OTCMKTS: PGSY) and Sterling Consolidated Corp (OTCBB: STCC) were all the subject of a few paid promotions as recently as last week but they sure did not start the new week out right because all were sinking on Monday. So are these small cap stocks that are either the subject of promotions or investor awareness campaigns hot or not? Here is a quick reality check:
Best Low Price Companies To Buy Right Now: Aqua America Inc.(WTR)
Aqua America, Inc., through its subsidiaries, operates regulated utilities that provide water or wastewater services in the United States. The company serves residential, commercial, fire protection, industrial, and other water and wastewater customers in Pennsylvania, Texas, North Carolina, Ohio, Illinois, New Jersey, New York, Florida, Indiana, Virginia, Maine, Missouri, and Georgia. It also provides water and wastewater services through operating and maintenance contracts with municipal authorities and other parties, as well as sludge hauling, septage and grease services, and backflow prevention services. The company was formerly known as Philadelphia Suburban Corporation and changed its name to Aqua America, Inc. in 2004. Aqua America, Inc. was founded in 1968 and is based in Bryn Mawr, Pennsylvania.
Advisors' Opinion:- [By David Dittman]
Answer: Our favorite water utilities–American Water Works, Aqua America Inc (NYSE: WTR), Connecticut Water Service Inc (NSDQ: CTWS)–are solid dividend growers throughout the cycle, and they all have pretty good growth prospects because of the abundance of small-scale municipal water utilities in their footprints.
Best Low Price Companies To Buy Right Now: The AES Corporation(AES)
The AES Corporation, through its subsidiaries, operates as a power company in Latin America, Africa, North America, Europe, the Middle East, and Asia. The company owns and operates two businesses, Generation and Utilities. The Generation business owns and/or operates power plants to generate and sell power to wholesale customers, such as utilities and other intermediaries. It generates electricity through various sources, including coal, gas, fuel oil, biomass, hydroelectric, wind, and solar. The Utilities business owns and/or operates utilities to distribute, transmit, and sell electricity to end-user customers in the residential, commercial, industrial, and governmental sectors. As of December 31, 2010, the company owned electricity generation and distribution facilities with a total capacity of approximately 40,500 megawatts and distribution networks serving approximately 12 million people in 28 countries. The AES Corporation was founded in 1981 and is based in Arlingto n, Virginia.
Advisors' Opinion:- [By Anna Prior]
SunEdison Inc.(SUNE) on Thursday said it completed its purchase of AES Corp.'s(AES) 50% ownership stake in the Silver Ridge Power LLC joint venture.
Best Low Price Companies To Buy Right Now: NxStage Medical Inc.(NXTM)
NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product, the NxStage System One, is a portable hemodialysis system used for home hemodialysis and a range of dialysis therapies for chronic home hemodialysis treatment, and the treatment of acute kidney failure and fluid overload. The NxStage System One comprises components, such as The NxStage Cycler, a compact portable electromechanical device; The NxStage Cartridge, a single-use integrated treatment cartridge; and premixed dialysate for hemodialysis applications. The company also sells a line of extracorporeal disposable products for use primarily for in-center dialysis treatments for patients with end-stage renal disease (ESRD); and needles and blood tubing sets primarily to dialysis clinics for the treatment of ESRD. NxStage Medical, Inc. markets its products primaril y to dialysis clinics, nephrologists, and hospitals through distributors and sales representatives in the United States, Mexico, and Europe. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. founded in 1998 and is headquartered in Lawrence, Massachusetts.
Advisors' Opinion:- [By John Udovich]
Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with�the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA)�and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM).�
No comments:
Post a Comment